i don't know his track record, so can't say. It seems more like Biocentury or the pinksheet though. he doesn't really get into the fundamentals, or the science. or trial design, etc.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.